<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0">
<channel>
<title>Jefferson Institute of Molecular Medicine Papers and Presentations</title>
<copyright>Copyright (c) 2013 Thomas Jefferson University All rights reserved.</copyright>
<link>http://jdc.jefferson.edu/jimmfp</link>
<description>Recent documents in Jefferson Institute of Molecular Medicine Papers and Presentations</description>
<language>en-us</language>
<lastBuildDate>Fri, 22 Feb 2013 17:06:29 PST</lastBuildDate>
<ttl>3600</ttl>








<item>
<title>Caveolin-1, TGF-β receptor internalization, and the pathogenesis of systemic sclerosis</title>
<link>http://jdc.jefferson.edu/jimmfp/4</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/jimmfp/4</guid>
<pubDate>Tue, 20 Mar 2012 08:11:36 PDT</pubDate>
<description>
	<![CDATA[
	<p><strong>PURPOSE OF REVIEW:</strong> To review the scientific literature supporting the participation of caveolin-1 in the pathogenesis of tissue fibrosis and the notion that modulation of the caveolin-1 pathway may represent a novel treatment for systemic sclerosis and other fibrotic diseases.</p>
<p><strong>RECENT FINDINGS:</strong> Caveolin-1 plays an important role in the regulation of transforming growth factor-beta (TGF-beta) signaling owing to its participation in TGF-beta receptor internalization. TGF-beta receptor internalized through caveolin-1 lipid rafts undergoes rapid degradation, effectively decreasing TGF-beta signaling. Studies have shown that caveolin-1 knockdown in vitro markedly increased collagen gene expression in normal human lung fibroblasts. Caveolin-1 was reduced in affected systemic sclerosis lungs and skin and in idiopathic pulmonary fibrosis lung tissues and fibroblasts. Increasing caveolin-1 expression markedly improved bleomycin-induced pulmonary fibrosis. Restoration of caveolin bioavailability employing penetratin, a cell-permeable peptide carrier for a bioactive caveolin-1 fragment, abrogated TGF-beta activation of cultured human dermal fibroblasts. Systemic administration of penetratin-caveolin-1 peptide to mice with bleomycin-induced lung fibrosis reduced fibrosis.</p>
<p><strong>SUMMARY:</strong> Caveolin-1 plays an important role in the regulation of TGF-beta signaling and participates in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis. Restoration of caveolin function employing active caveolin-1 fragments coupled to cell-permeable carrier peptides may represent a novel approach for their treatment.</p>

	]]>
</description>

<author>Francesco Del Galdo et al.</author>


</item>






<item>
<title>Effect of protein kinase C delta (PKC-δ) inhibition on the transcriptome of normal and systemic sclerosis human dermal fibroblasts in vitro.</title>
<link>http://jdc.jefferson.edu/jimmfp/3</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/jimmfp/3</guid>
<pubDate>Wed, 08 Feb 2012 08:27:22 PST</pubDate>
<description>
	<![CDATA[
	<p>Previous studies demonstrated that protein kinase C- δ (PKC-δ) inhibition with the selective inhibitor, rottlerin, resulted in potent downregulation of type I collagen expression and production in normal human dermal fibroblasts and abrogated the exaggerated type I collagen production and expression in fibroblasts cultured from affected skin from patients with the fibrosing disorder systemic sclerosis (SSc). To elucidate the mechanisms involved in the ability of PKC-δ to regulate collagen production in fibroblasts, we examined the effects of PKC-δ inhibition on the transcriptome of normal and SSc human dermal fibroblasts. Normal and SSc human dermal fibroblasts were incubated with rottlerin (5 µM), and their gene expression was analyzed by microarrays. Pathway analysis and gene ontology analysis of differentially expressed genes in each comparison were performed. Identification of significantly overrepresented transcriptional regulatory elements (TREs) was performed using the Promoter Analysis and Interaction Network Toolset (PAINT) program. PKC-δ activity was also inhibited using RNA interference (siRNA) and by treating fibroblasts with a specific PKC-δ inhibitory cell permeable peptide. Differential gene expression of 20 genes was confirmed using real time PCR. PKC-δ inhibition caused a profound change in the transcriptome of normal and SSc human dermal fibroblasts in vitro. Pathway and gene ontology analysis identified multiple cellular and organismal pathways affected by PKC-δ inhibition. Furthermore, both pathway and PAINT analyses indicated that the transcription factor NFκB played an important role in the transcriptome changes induced by PKC-δ inhibition. Multiple genes involved in the degradation of the extracellular matrix components were significantly reduced in SSc fibroblasts and their expression was increased by PKC-δ inhibition. These results indicate that isoform-specific inhibition of PKC-δ profibrotic effects may represent a novel therapeutic approach for SSc and other fibrotic diseases.</p>

	]]>
</description>

<author>Peter J Wermuth et al.</author>


</item>






<item>
<title>NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis.</title>
<link>http://jdc.jefferson.edu/jimmfp/2</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/jimmfp/2</guid>
<pubDate>Wed, 08 Dec 2010 08:25:44 PST</pubDate>
<description>
	<![CDATA[
	<p>OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is a generalised fibrotic disorder occurring in certain individuals with renal insufficiency exposed to gadolinium-based contrast agents (GdBCA) for MRI. Histopathological examination of affected tissues shows increased numbers of activated macrophages. To elucidate the mechanisms responsible for macrophage activation, the effects of the GdBCA Omniscan on normal human macrophage global gene expression, chemokine production and nuclear factor κB (NFκB) activation was examined.</p>
<p>METHODS: Normal human monocyte-derived macrophages were incubated with Omniscan (50 mM) and their gene expression analysed by microarrays and real-time PCR. Macrophage chemokine production was assayed by multiplex ELISA. NFκB activation was assessed by NFκB nuclear localisation and quantitation of intracellular levels of inducible nitric oxide synthase (iNOS) protein. A specific cell-permeable NFκB peptide inhibitor was used to abrogate NFκB stimulation of chemokine and iNOS protein levels. CCL8/MCP-2 in affected skin of patients with NSF was examined by indirect immunofluorescence.</p>
<p>RESULTS: Omniscan caused a profound change in the transcriptome of differentiated human normal macrophages in vitro, including a large increase in the expression of genes encoding CC and CXC chemokines. It induced rapid nuclear localisation of NFκB and stimulation of iNOS protein levels and chemokine production which were blocked by an NFκB inhibitory peptide. CCL8/MCP-2, the most upregulated chemokine following in vitro macrophage exposure to Omniscan, was strongly increased in NSF-affected skin.</p>
<p>CONCLUSION: The GdBCA Omniscan induces potent stimulation of macrophage gene expression, NFκB activation and increased NFκB-mediated production of CC and CXC chemokines and iNOS. These alterations may play a crucial role in the pathogenesis of NSF.</p>

	]]>
</description>

<author>Francesco Del Galdo et al.</author>


<category>Cell Differentiation</category>

<category>Cell Nucleus</category>

<category>Cells, Cultured</category>

<category>Chemokine CCL8</category>

<category>Chemokines</category>

<category>Contrast Media</category>

<category>Gadolinium DTPA</category>

<category>Gene Expression Regulation</category>

<category>Humans</category>

<category>Macrophages</category>

<category>NF-kappa B</category>

<category>Nephrogenic Fibrosing Dermopathy</category>

<category>Nitric Oxide Synthase Type II</category>

<category>Polymerase Chain Reaction</category>

<category>Signal Transduction</category>

<category>Skin</category>

</item>






<item>
<title>Osteoarthritis associated with estrogen deficiency.</title>
<link>http://jdc.jefferson.edu/jimmfp/1</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/jimmfp/1</guid>
<pubDate>Sat, 07 Aug 2010 09:47:00 PDT</pubDate>
<description>
	<![CDATA[
	<p>Osteoarthritis (OA) affects all articular tissues and finally leads to joint failure. Although articular tissues have long been considered unresponsive to estrogens or their deficiency, there is now increasing evidence that estrogens influence the activity of joint tissues through complex molecular pathways that act at multiple levels. Indeed, we are only just beginning to understand the effects of estrogen deficiency on articular tissues during OA development and progression, as well as on the association between OA and osteoporosis. Estrogen replacement therapy and current selective estrogen receptor modulators have mixed effectiveness in preserving and/or restoring joint tissue in OA. Thus, a better understanding of how estrogen acts on joints and other tissues in OA will aid the development of specific and safe estrogen ligands as novel therapeutic agents targeting the OA joint as a whole organ.</p>

	]]>
</description>

<author>Jorge A Roman-Blas et al.</author>


<category>Animals</category>

<category>Estrogens</category>

<category>Female</category>

<category>Humans</category>

<category>Joints</category>

<category>Osteoarthritis</category>

<category>Osteoporosis</category>

<category>Postmenopause</category>

</item>





</channel>
</rss>
